Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-070926
Filing Date
2025-07-25
Accepted
2025-07-25 20:14:43
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9063
2 EXHIBIT 1 tm2521807d1_ex-1.htm EX-24.1 6385
3 EXHIBIT 2 tm2521807d1_ex-2.htm EX-99.1 4401
  Complete submission text file 0001104659-25-070926.txt   21980
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Subject) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-54847 | Film No.: 251152782
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001
Business Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001 212-478-0000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A